IGF1 (CA)19 Repeat and IGFBP3 -202 A/C Genotypes and the Risk of Prostate Cancer in Black and White Men
- Joellen M. Schildkraut1,6,
- Wendy Demark-Wahnefried1,2,
- Robert M. Wenham3,
- Janet Grubber1,
- Amy S. Jeffreys7,
- Steven C. Grambow4,7,
- Jeffrey R. Marks5,
- Patricia G. Moorman1,6,
- Cathrine Hoyo1,6,
- Shazia Ali3 and
- Philip J. Walther2
- 1Program of Cancer Prevention, Detection and Control Research; 2Department of Surgery, Division of Urology; 3Department of Obstetrics and Gynecology, Division of Oncology; 4Department of Biostatistics and Bioinformatics; 5Experimental Surgery; 6Department of Community and Family Medicine, Division of Prevention, Duke University Medical Center; and 7Epidemiologic Research and Information Center, Veterans Administration Medical Center, Durham, North Carolina
- Requests for reprints:
Joellen M. Schildkraut, Duke Comprehensive Cancer Center, Room 238, Hanes House, P.O. Box 2949, Durham, NC 27710. Phone: 919-681-4761; Fax: 919-681-4785. E-mail: schil001{at}mc.duke.edu
Abstract
We investigated the relationship between the insulin-like growth factor-1 (IGF1) cytosine-adenine repeat (CA)19 polymorphism located upstream of the gene's transcription start site, the insulin-like growth factor binding protein-3 (IGFBP3) −202 A/C promoter region polymorphism, and prostate cancer risk in Black and White men. Study subjects were U.S. veterans ages 41 to 75 years identified at the Durham Veterans Administration Medical Center over a 2.5-year period. Controls (n = 93) were frequency matched to cases (n = 100) based on race (Black or White) and age. Multivariable unconditional logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI) for the associations between the polymorphisms and prostate cancer risk. For Blacks and Whites combined, an inverse association between prostate cancer and being homozygous for the most common IGF1 repeat allele, (CA)19, (adjusted OR, 0.3; 95% CI, 0.1-0.7) was observed. Similar associations were noted for both Blacks (OR, 0.2; 95% CI, 0.0-0.8) and Whites (OR, 0.4; 95% CI, 0.1-1.6) separately. No statistically significant associations between the IGFBP3 C allele and prostate cancer were noted for Blacks (adjusted OR, 2.3; 95% CI, 0.8-6.2) or Whites (OR, 1.0; 95% CI, 0.3-3.1). The prevalence of the homozygous IGF1 (CA)19 genotype was much lower in Black controls (21%) than White controls (46%), which may, in part, explain the increased prostate cancer incidence in Black versus White men. Further research is needed to confirm these findings.
Footnotes
-
Grant support: Office of Research and Development, Cooperative studies Program, Department of Veterans Affairs grant 708D and NIH grants R21-CA69733, RO1 CA85740, and RO1 CA14236.
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
Note: The views expressed in this article are those of the authors and do not necessarily represent the view of the Department of Veterans Affairs.
-
- Accepted September 7, 2004.
- Received June 11, 2004.
- Revision received August 31, 2004.
